BioCentury
ARTICLE | Clinical News

CAP-1002: Phase I/II data

August 11, 2014 7:00 AM UTC

The open-label, dose-escalation Phase I portion of the U.S. Phase I/II ALLSTAR trial showed that CAP-1002 improved ejection fraction from an average of 38.9% at baseline to 44.1% at 6 months. Capricor also said CAP-1002 led to “quantifiable improvements” in measurements of infarct size, viable mass and regional function, but could not be reached for details. The company is enrolling about 300 patients who had an MI in the double-blind, placebo-controlled Phase II portion of ALLSTAR to evaluate single intracoronary infusions of CAP-1002. ...